Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease?
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
20
12
2019
accepted:
17
03
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
14
9
2021
Statut:
epublish
Résumé
To investigate the immunologic impact of a single cycle of rituximab (RTX) in children and adolescents with immune-mediated disorders, we evaluated B cells and immunoglobulin levels of 20 patients with neuroimmunologic, nephrologic, dermatologic, and rheumatologic disorders treated under recommended guidelines. Retrospective study of immunologic changes in children (aged ≤18 years) diagnosed with immune-mediated disorders in which RTX was prescribed between June 2014 and February 2019. Patients were excluded if they had prior diagnosis of malignant disease or primary immunodeficiency. Patients were clinically and immunologically followed up every 3 months. Only patients having received a single cycle of RTX and with a follow-up greater than 12 months were included in the analysis of persistent dysgammaglobulinemia. Twenty children were included. Median age at RTX treatment was 12.8 years (interquartile range [IQR] 6.6-15.5 years). Median follow-up was 12.6 months (IQR 10.2-24 months). Of the 14 patients eligible for persistent dysgammaglobulinemia analysis (3 had received RTX retreatment, 2 had <12 months post-RTX follow-up, and in 1 data for this time point was missing), 2/14 (14%) remained with complete B-cell depletion, and 5/14 (36%) had dysgammaglobulinemia. Patients with dysgammaglobulinemia were younger (7.8 vs 15.6 years, In our cohort, single-cycle RTX-induced dysgammaglobulinemia was enhanced in patients with neuroimmunologic diseases. Further studies are needed to confirm this observation.
Identifiants
pubmed: 32376706
pii: 7/4/e724
doi: 10.1212/NXI.0000000000000724
pmc: PMC7217658
pii:
doi:
Substances chimiques
Immunologic Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Immunotherapy. 2018 Jun;10(8):713-728
pubmed: 29569510
JAMA Netw Open. 2018 Nov 2;1(7):e184169
pubmed: 30646343
Scand J Immunol. 2011 Nov;74(5):502-10
pubmed: 21815909
Int Rev Immunol. 2017 Nov 2;36(6):352-359
pubmed: 28800262
PLoS One. 2012;7(5):e37626
pubmed: 22629432
Pediatr Nephrol. 2009 Jul;24(7):1321-8
pubmed: 19421786
Cancers (Basel). 2015 Jan 29;7(1):305-28
pubmed: 25643241
Am J Transplant. 2008 Dec;8(12):2607-17
pubmed: 18808404
Cancer Treat Rev. 2013 Oct;39(6):632-9
pubmed: 23219151
Front Immunol. 2019 Feb 08;10:33
pubmed: 30800120
J Autoimmun. 2015 Feb;57:60-5
pubmed: 25556904
Cancer Treat Rev. 2005 Oct;31(6):456-73
pubmed: 16054760
Arthritis Care Res (Hoboken). 2017 Jun;69(6):857-866
pubmed: 27428176
Rheumatology (Oxford). 2019 Feb 1;58(2):331-335
pubmed: 30358861
PLoS One. 2018 Jan 8;13(1):e0190425
pubmed: 29309416
Blood. 2006 Apr 1;107(7):2639-42
pubmed: 16352811
Pediatr Blood Cancer. 2008 Apr;50(4):822-5
pubmed: 17570702
Curr Treatm Opt Rheumatol. 2018 Mar;4(1):14-28
pubmed: 29780690
Neurology. 2014 Jul 8;83(2):142-50
pubmed: 24920861
Arthritis Rheum. 2008 Jan;58(1):5-14
pubmed: 18163518
Curr Opin Rheumatol. 2016 May;28(3):251-8
pubmed: 27027812
Lancet. 2001 Nov 3;358(9292):1511-3
pubmed: 11705566
Pediatr Rheumatol Online J. 2019 Aug 28;17(1):61
pubmed: 31462263
Arthritis Res Ther. 2013;15 Suppl 1:S3
pubmed: 23566754
J Infect. 2015 Jun;71 Suppl 1:S112-20
pubmed: 25934325
J Pediatr. 2013 Jun;162(6):1252-8, 1258.e1
pubmed: 23269206
BMC Musculoskelet Disord. 2014 May 25;15:178
pubmed: 24884562
J Immunol. 2006 Feb 15;176(4):2600-9
pubmed: 16456022
J Neurol. 2018 May;265(5):1123
pubmed: 29627939